Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers

October 1, 2014 Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “We wanted to study how …

European Committee for Medicinal Products for Human Use approves update to Gardasil® SmPC to include long-term protection data

Immunogenicity and effectiveness data from long-term follow-up of Gardasil® studies demonstrates sustained protection against HPV 6, 11, 16 and 18 disease September 12, 2014 Sanofi Pasteur MSD announced today that the Summary of Product characteristics (SmPC) of Gardasil has been updated to include new data related to long-term protection. (1) The duration of protection of Gardasil is being monitored through different …

Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin

August 11th, 2014 Sanofi and MannKind Corporation MNKD announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Under the collaboration …

Sanofi Pasteur MSD: Who’s running the show

Formed through the merger of Sanofi Pasteur and Merck, Sanofi Pasteur MSD ranks as one of the top vaccine companies in the world. Marketing some of the best selling vaccines developed between the two companies, Sanofi Pasteur MSD represents a sizeable chunk of the vaccines market. With big notable products including: HPV vaccine Gardasil ($2.16 billion in 2013); Vaxigrip ($1.39 …

Gardasil: CHMP Grants Positive Opinion for New Indication, for the Prevention of Anal Cancers and Anal Precancerous Lesions, in the European Union

European Committee for Medicinal Products for Human Use evaluated positively a new indication for the prevention of anal cancers and precancerous lesions for Gardasil April 30, 2014 Sanofi Pasteur MSD announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for Gardasil® to be used for the prevention of anal precancerous …